Remus Pharmaceuticals reported a 20% year-on-year increase in consolidated net profit to ₹46 crore for the financial year ended March 31, 2026, supported by a 38% rise in revenue to ₹854 crore. The company’s operational EBITDA grew 24% to ₹57 crore, reflecting strong execution across its global markets. For the second half of FY26, consolidated revenue stood at ₹453 crore, a 30% increase, with a net profit of ₹25 crore, up 20% year-on-year.

The financial performance was driven by a strategic mix of B2B and emerging B2C businesses. The B2C segment’s contribution to revenue increased from 4% in the previous year to 14% in FY26, while the B2B segment contributed the remaining 86%. Management attributed the growth to expanding global footprint, particularly in Latin America, and the launch of niche products in the CNS and urology portfolios.

Financial Highlights

The company disclosed the following financial metrics for the period under review:

Operational Expansion

During the period, Remus Pharmaceuticals expanded its presence in Latin America through product in-licensing and regulatory filings. Key launches included Rifaximin and Fexofenadine in Mexico, Chile, and Peru, and Rivastigmine patches in Venezuela. The company also expanded its urology portfolio with the launch of Mirabegron across four Latin American countries.

In Asia and ASEAN markets, the company licensed Peg-filgrastim and Filgrastim PFS injections for the Philippines and Vietnam. In the Middle East, it secured a NUPCO tender with Saudi Arabia for Topiramate capsules. Additionally, the company initiated filings for semaglutide tablets and injections in non-patented emerging markets, marking its entry into the GLP-1 and anti-obesity segment.

Strategic Outlook

Management highlighted that the B2C segment is expected to grow by approximately 30% in FY27, while the B2B segment is projected to grow between 25% and 30%. The company plans to launch 26 products in Bolivia under the B2C segment in the coming months and has registered 126 brand names and trademarks to support this expansion.

Margins in FY26 were impacted by investments in R&D and bioequivalence studies, which management views as critical for accessing high-barrier markets like Chile and Mexico. The company expects these investments to yield better margins in the current financial year as products with clinical trials are commercialized in markets with fewer competitors.

Remus Pharmaceuticals has announced its audited standalone and consolidated financial results for the financial year and half-year ended March 31, 2026. The company reported a significant increase in profitability and operational growth for the full fiscal year, driven by strategic expansion and product launches across international markets. Additionally, the company released an investor presentation detailing its performance highlights and strategic developments for the period.

FY26 Financial Performance

For the full year FY26, the company achieved a revenue from operations of ₹853.63 Cr, compared to ₹620.36 Cr in FY25, representing a year-on-year growth of 37.60%. Profit After Tax (PAT) for the period stood at ₹46.17 Cr, a 20.18% increase from ₹38.42 Cr in the previous year. EBITDA also saw a robust rise of 24.08%, reaching ₹56.69 Cr in FY26 from ₹45.69 Cr in FY25.

Dividend Declaration

The Board of Directors has recommended a final dividend of ₹0.50 per equity share of face value ₹10 each for the financial year 2025-26. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.

H2 FY26 Highlights

The second half of the fiscal year continued the growth trajectory. H2 FY26 revenue reached ₹453.43 Cr, a 30.39% increase compared to ₹347.75 Cr in H2 FY25. Net profit for H2 FY26 rose to ₹24.58 Cr, up 19.51% from ₹20.57 Cr in the corresponding prior period. Sequentially, revenue grew by 13.30% and PAT by 13.86% over H1 FY26 figures.

The following table summarises the consolidated financial performance for FY26 and H2 FY26:

Strategic Developments

During H2 FY26, Remus Pharmaceuticals expanded its commercial presence into four new markets: Myanmar, Nicaragua, North Macedonia, and Madagascar. The company in-licensed key products such as Rifaximin and Fexofenadine for markets including Mexico and Vietnam. It also initiated filings for Semaglutide tablets and injections in emerging markets and secured government tenders in Nicaragua and North Macedonia. The company successfully cleared the Peru DIGEMID audit in February 2026.